N-Acetyl Selank Amidate
Other names:Selanc, TP-7, UNII- TS9JR8EP1G, N-Acetyl Selankamidate, N-Acetyl Selank
N-Acetyl Selank Amidate can be considered an enhanced version of Selank. Extensive research has demonstrated that N-Acetyl Selank Amidate improves upon every aspect of Selank, including its potency, half-life, absorbability, and ability to cross the blood-brain barrier. These enhancements contribute to the amplification of Selank’s effects. Animal studies have indicated that Selank protects the central nervous system from disease and trauma, reduces anxiety, enhances learning and memory, and influences the blood clotting process. Although further research is needed, the study of Selank and other glyprolines provides valuable insights into how a single peptide can modify DNA expression patterns to yield significant outcomes.
◐ Production capacity: Provide customization
◐ Large Factory Professional Manufacturers & Factory
◐ Production Carried OUT Under CGMP Regulation and Trackable
◐ ISO9001 & ISO14000
Get a Bulk quotation
If you need a larger quantity. Please fill in the form, our BD (Business Development) will provide you with a competitive quotation.
Amino Acid Sequence:
Selanc, TP-7, UNII – TS9JR8EP1G
N-Acetyl Selank Amidate Peptide dosage calculator
 A. Volkova et al., “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission,” Front. Pharmacol., vol. 7, p. 31, Feb. 2016, doi: 10.3389/fphar.2016.00031. [PubMed]
 A. Kasian et al., “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats,” Behav. Neurol., vol. 2017, p. 5091027, 2017, doi: 10.1155/2017/5091027. [PubMed].
 Z. V. Bakaeva et al., “Glyprolines exert protective and repair-promoting effects in the rat stomach: potential role of the cytokine GRO/CINC-1,” J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc., vol. 67, no. 2, pp. 253–260, Apr. 2016. [PubMed]
 O. N. Uchakina et al., “[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 108, no. 5, pp. 71–75, 2008. [PubMed]
 A. A. Zozulia et al., “[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 108, no. 4, pp. 38–48, 2008. [PubMed]
 L. A. Liapina, V. E. Pastorova, T. I. Obergan, G. E. Samonina, I. P. Ashmarin, and N. F. Miasoedov, “[Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application],” Izv. Akad. Nauk. Ser. Biol., no. 2, pp. 193–203, Apr. 2006. [PubMed]
 E. Y. Rogozinskaya and M. G. Lyapina, “Anticoagulant Effects of Arginine-Containing Peptides of the Glyproline Family (His-Phe-Arg-Trp-Pro-Gly-Pro and Thr-Lys-Pro-Arg-Pro-Gly-Pro) Revealed by Thromboelastography,” Bull. Exp. Biol. Med., vol. 164, no. 2, pp. 170–172, Dec. 2017, doi: 10.1007/s10517-017-3950-4. [PubMed]